CD8A and myeloid sarcoma: Although several reports have also indicated largely intact spike antigen–specific T cell responses in vaccinated patients with MS treated with anti-CD20 mAbs (19, 24), there currently are no available data comparing SARS-CoV-2 vaccine–specific CD4+ and CD8+ T cell reactivity across patients treated with different DMTs.